Caladrius Biosciences, Inc.

Welcome to Caladrius Biosciences second quarter 2021 financial results and business update conference call. Currently all participants are in listen only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by one on your touchtone phone. If anyone has difficulty hearing the conference call, please press star zero for operator assistance. As a reminder, this call is being recorded today, Thursday, August 5th, 2021. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Caladrius. Please go ahead, sir.

Thank you, Operator, and good afternoon, everyone. Welcome to Caladrius' second quarter 2021 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, and James Nisko, Vice President of Finance and Treasury. Earlier today, we issued a press release announcing our second quarter 2021 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release, or if you would like to be added to the company's email distribution list, please email me at jmendito at caladrius.com. Before we begin, I remind you that the comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Caladrius. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-K, 10-Q, and 8-K, which identify specific factors that might cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, August 5, 2021. Collideus Biosciences undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. Please keep in mind that the company continues to conduct calls from different locations during the COVID-19 pandemic, so we appreciate your patience should we have any technical difficulties. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. I hope that you are all well and you are experiencing the ebbing of the COVID-19 pandemic and any effects that it may have had on you or your family. Thank you for joining us on our call today to discuss our second quarter 2021 financial results and recent business highlights. During the second quarter and first six months of 2021, we continue to advance our clinical development programs and strengthen our financial position, which we believe gives us the means to fund our operations for the next several years based on our current development plans, while also allowing us to explore additional pipeline expansion opportunities. Most notably, we delivered on a number of strategic priorities in support of our autologous CD34 cell technology-based clinical pipeline, about which I will further discuss following the prepared remarks covering the financial results. And with that, I will now turn the call over to James Nisko, our Vice President of Finance and Treasury, who will review and provide commentary on our quarterly financial results. James?